Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progres
Combination Trials with Avutometinib (VS-6766) Ongoing as Part of Development Program Designed to Maximize Potential Across RAS Pathway-Driven TumorsCompany Confirms Q4 FDA Meeting Based on Encouraging Results to Date in Ongoing RAMP 201 Trial of Avutometinib (VS-6766) ± Defactinib in Low-Grade Serous Ovarian Cancer...
United States Nate Liabraaten Dan Calkins Elisa Buffington Brian Stuglik Chugai Pharmaceutical Co Ltd
Source: pharmiweb.com